These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35934286)

  • 1. Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis.
    Dulai PS; Feagan BG; Sands BE; Chen J; Lasch K; Lirio RA
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):456-466.e7. PubMed ID: 35934286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial.
    Yarur AJ; Chiorean MV; Panés J; Jairath V; Zhang J; Rabbat CJ; Sandborn WJ; Vermeire S; Peyrin-Biroulet L
    J Crohns Colitis; 2024 Jun; 18(6):885-894. PubMed ID: 38245818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis.
    Stevens TW; Gecse K; Turner JR; de Hertogh G; Rubin DT; D'Haens GR
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2333-2342. PubMed ID: 32801008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis.
    Naganuma M; Kobayashi T; Nasuno M; Motoya S; Kato S; Matsuoka K; Hokari R; Watanabe C; Sakamoto H; Yamamoto H; Sasaki M; Watanabe K; Iijima H; Endo Y; Ichikawa H; Ozeki K; Tanida S; Ueno N; Fujiya M; Sako M; Takeuchi K; Sugimoto S; Abe T; Hibi T; Suzuki Y; Kanai T
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1102-1111.e5. PubMed ID: 31394288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.
    Sandborn WJ; Panés J; Zhang H; Yu D; Niezychowski W; Su C
    Gastroenterology; 2016 Jan; 150(1):96-102. PubMed ID: 26376350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission.
    Guardiola J; Lobatón T; Rodríguez-Alonso L; Ruiz-Cerulla A; Arajol C; Loayza C; Sanjuan X; Sánchez E; Rodríguez-Moranta F
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1865-70. PubMed ID: 24993368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
    Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.
    Ma C; Lumb R; Walker EV; Foshaug RR; Dang TT; Verma S; Huang VW; Kroeker KI; Wong K; Dieleman LA; Fedorak RN; Halloran BP
    Inflamm Bowel Dis; 2017 Sep; 23(9):1643-1649. PubMed ID: 28644184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission.
    Kawashima K; Oshima N; Kishimoto K; Kataoka M; Fukunaga M; Kotani S; Sonoyama H; Oka A; Mishima Y; Kazumori H; Ishikawa N; Araki A; Ishihara S
    Inflamm Bowel Dis; 2023 Mar; 29(3):359-366. PubMed ID: 35583193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.
    Reinisch W; Bressler B; Curtis R; Parikh A; Yang H; Rosario M; Røseth A; Danese S; Feagan B; Sands BE; Ginsburg P; Dassopoulos T; Lewis J; Xu J; Wyant T
    Inflamm Bowel Dis; 2019 Mar; 25(4):803-810. PubMed ID: 30295811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients.
    Cannatelli R; Bazarova A; Zardo D; Nardone OM; Shivaji U; Smith SCL; Gkoutos G; Ricci C; Gui XS; Ghosh S; Iacucci M
    Inflamm Bowel Dis; 2021 Apr; 27(5):647-654. PubMed ID: 32592477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histologic Evaluation Using the Robarts Histopathology Index in Patients With Ulcerative Colitis in Deep Remission and the Association of Histologic Remission With Risk of Relapse.
    Park J; Kang SJ; Yoon H; Park J; Oh HJ; Na HY; Lee HS; Shin CM; Park YS; Kim N; Lee DH
    Inflamm Bowel Dis; 2022 Nov; 28(11):1709-1716. PubMed ID: 35016209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis.
    Theede K; Holck S; Ibsen P; Ladelund S; Nordgaard-Lassen I; Nielsen AM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1929-36.e1. PubMed ID: 26051392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease.
    Kedia S; Jain S; Goyal S; Bopanna S; Yadav DP; Sachdev V; Sahni P; Pal S; Dash NR; Makharia G; Travis SPL; Ahuja V
    Dig Dis Sci; 2018 Oct; 63(10):2747-2753. PubMed ID: 29948556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: faecal calprotectin and histologic remission in ulcerative colitis.
    D'Amico F; Bonovas S; Danese S; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2020 Apr; 51(7):689-698. PubMed ID: 32048751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
    Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
    Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis.
    Malvão LDR; Madi K; Esberard BC; de Amorim RF; Silva KDS; Farias E Silva K; de Souza HSP; Carvalho ATP
    Medicine (Baltimore); 2021 Jan; 100(3):e24058. PubMed ID: 33546007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.